Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$1.05 USD

1.05
1,448,351

+0.05 (5.45%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $1.04 -0.01 (-0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors

by Zacks Equity Research

The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

Implied Volatility Surging for CytomX Therapeutic (CTMX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to CytomX Therapeutic (CTMX) stock based on the movements in the options market lately.

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.67% and -5.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -15.38% and -10.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

by Zacks Equity Research

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

by Zacks Equity Research

CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 10.34% and -21.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre

by Zacks Equity Research

The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Moving Average Crossover Alert: CytomX Therapeutics (CTMX)

by Zacks Equity Research

CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

CytomX Therapeutics (CTMX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is CytomX Therapeutics (CTMX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CTMX) Outperforming Other Medical Stocks This Year?

Benjamin Rains headshot

Find Strong Stocks Ahead of Q2 Earnings Season with this First Profit Screener

by Benjamin Rains

We used our 'First Profit' stock screener to help investors find strong stocks that might be worth looking at in preparation for Q2 earnings season...

Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 4th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.